Back to results
US 9,844,594 B2Granted
Liquid formulations for an anti-TNF α antibody
AssigneeMerck Sharp & Dohme Corp.
InventorsValentyn Antochshuk, Amardeep Bhalla, Azher M. Hussain
Life of this patent
Estimating the term…
Abstract
The invention provides stable liquid formulations for a recombinant biopharmaceutical protein comprising a fully human anti-TNF monoclonal antibody.
Claims4
A stable liquid aqueous pharmaceutical formulation comprising:
- Adalimumab;
- 0.05 mg/ml Sodium Phosphate Dibasic, Heptahydrate;
- 1.35 mg/ml Sodium Phosphate, Monobasic, Monohydrate;
- 5.17 mg/ml Sodium Chloride;
- 40.50 mg/ml Trehalose dihydrate;
- 1.00 mg/ml Polysorbate 80;
- and
- water,
- having a pH of 5.3.
6 more elements
A stable liquid aqueous pharmaceutical formulation comprising:
- adalimumab;
- 0.05 mg/ml Sodium Phosphate Dibasic, Heptahydrate;
- 1.35 mg/ml Sodium Phosphate, Monobasic, Monohydrate;
- 5.17 mg/ml Sodium Chloride;
- 19.50 mg/ml Mannitol;
- 1.00 mg/ml Polysorbate 80;
- and
- water;
- having a pH of 5.3.
6 more elements
A stable liquid aqueous pharmaceutical formulation comprising:
- adalimumab;
- 1.62 mg/ml Sodium Phosphate Dibasic, Heptahydrate;
- 0.50 mg/ml Succinic acid;
- 5.17 mg/ml Sodium Chloride;
- 40.50 mg/ml Trehalose dihydrate;
- 1.00 mg/ml Polysorbate 80;
- and
- water,
- having a pH of 5.3.
6 more elements
A stable liquid aqueous pharmaceutical formulation comprising:
- adalimumab;
- 1.62 mg/ml Sodium Phosphate Dibasic, Heptahydrate;
- 0.50 mg/ml Succinic acid;
- 5.17 mg/ml Sodium Chloride
- 19.50 mg/ml Mannitol;
- 1.00 mg/ml Polysorbate 80;
- and
- water,
- having a pH of 5.3.
6 more elements
Dependencies are inferred from the claim text.